Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

NCT07362017

RecruitingPhase 3

Sponsor: Vanda Pharmaceuticals

Conditions: Moderate-to-severe Chronic Plaque Psoriasis

Interventions: Ponesimod

Countries: United States

An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Male and female subjects aged 18-65 years, inclusive
* BMI \>18 and \<40
* Minimum affected BSA of 10%
* PASI score ≥ 12
* PGA ≥ 3
* Diagnosed with moderate-to-severe plaque psoriasis

Exclusion Criteria:

* Diagnosis of generalized erythrodermic, generalized pustular (von Zumbusch), guttate, or palmoplantar psoriasis
* History of an allergic reaction or known and/or significant sensitivity to study drug
Locations (4)
  • Glendale, Arizona, United States
  • Fremont, California, United States
  • Rochester, New York, United States
  • Spokane, Washington, United States